Рецепт. 2022; : 178-183
Дезогестрелсодержащий контрацептив в лечении и профилактике миомы, дисменореи и эндометриоза
https://doi.org/10.34883/PI.2022.25.2.007Аннотация
В течение 12 месяцев обследовано 25 курящих женщин с межмышечными миомами матки клинически незначимых размеров (от 0,5 до 1,0 см в диаметре – ультразвуковая находка) в возрасте от 25 до 38 лет. Всем пациенткам был назначен дезогестрелсодержащий контрацептив Лактинет в непрерывном режиме с 1-го дня менструального цикла по 1 таблетке в сутки в одно и то же время без перерыва на менструацию. Была зарегистрирована стабилизация размеров клинически незначимых миоматозных узлов. Межменструальные кровянистые выделения продолжительностью от 7 до 12 дней, возникающие периодически в течение менструального цикла, были отмечены в период до 3 месяцев использования Лактинета у 9 женщин, в период до 6 месяцев – у 3 пациенток. Аменорея зафиксирована в период до 3 месяцев у 15 пациенток, через 6 месяцев – у 22 пациенток, через 9 и 12 мес. – у 25 женщин. К 12- му месяцу использования Лактинета предменструальный синдром и дисменорея были выявлены лишь у одной женщины.
Список литературы
1. Prilepskaja V. (ed.) A guide to contraception. Moscow: MEDpress-inform; 2010. 448 p. (in Russian)
2. Tihomirov A. Mioma. Pathogenetic justification of organ-preserving treatment. Moscow: 2013. 320 p. (in Russian)
3. Tihomirov A., Kazenashev V., Ledenkova A. Laktinet is a possible extension of the range of applications. RMJ. Mother and child. 2013;23:1114. (in Russian)
4. Vihljaeva E., Nikolaeva E. The possibility of choosing and acceptability of various methods of contraception after childbirth. Obstetrics and gynecology. 2003;6:20–4. (in Russian)
5. Jaglov V. Contraception after childbirth. Cons. Med. 2001;13(5):86–91. (in Russian)
6. Prilepskaja V. (ed.) A guide to contraception. Moscow: MEDpress-inform; 2006;110–180.
7. Prilepskaja V., Mezhevitinova E., Nazarova N. Hormonal contraception. Moscow: GJeOTAR-Media; 2011;24–46. (in Russian)
8. Savelev E. (2003) Hyperplastic processes of the endometrium in women of reproductive age after cesarean section (PhD Thesis), Kazan. (in Russian)
9. Chivilgina V. (2003) Substantiation of differentiated contraceptive technologies in women in the postpartum period (PhD Thesis), Moscow, 2003.
10. Curtis K.M., Jatlaoui T.C., Tepper N.K. Selected Practice Recommendations for Contraceptive Use, 2016. MMWR Recomm Rep. 2016;65(4):1–66. doi: 10.15585/mmwr.rr6504a1.
11. Tepper N.K., Whiteman M.K., Marchbanks P.A. Progestin-only contraception and thromboembolism: A systematic review. Contraception. 2016;94(6):678–700. doi: 10.1016/j.contraception.2016.04.014.
12. Trussell J. Contraceptive failure in the United States. Contraception. 2011;83(5):397–404. doi: 10.1016/j.contraception.2011.01.021.
13. World Health Organization. Medical Eligibility Criteria for Contraceptive Use. 5th ed. Geneva: World Health Organization; 2015.
14. Kiselev V., Ljashenko A. Molecular mechanisms of regulation of hyperplastic processes. Moscow: Dimitrejd Grafik Grupp; 2005. 348 p. (in Russian)
15. Linde V., Tatarova N. Endometriosis. Patenogenesis, clinical picture, diagnosis and treatment. Moscow: GJeOTAR-Media, 2010. 192 p. (in Russian)
16. Dixon D., Flake G.P., Moore A.B. Cell proliferation and apoptosis in human uterine leiomyomas and myometria. Virchows Arch. 2002;441(1):53–62. doi: 10.1007/s00428-001-0568-7.
17. Dizerega G.S., Barber D.L., Hodgen G.D. Endometriosis: role of ovarian steroids in initiation, maintenance, and suppression. Fertil Steril. 1980;33(6):649–53. doi: 10.1016/s0015-0282(16)44780-1.
18. Practice Committee of American Society for Reproductive Medicine Treatment of pelvic pain associated with endometriosis. Fertil Steril. 2008;90(5 Suppl.):260–269.
Recipe. 2022; : 178-183
Desogestrel-containing Contraceptive in the Treatment and Prevention of Fibroids, Dysmenorrhea and Endometriosis
https://doi.org/10.34883/PI.2022.25.2.007Abstract
Within 12 months, 25 smoking women with intermuscular uterine fibroids of clinically insignificant size (from 0.5 to 1.0 cm in diameter – ultrasound finding) aged 25 to 38 years were examined. All patients were prescribed desogestrel-containing contraceptive Lactinet in continuous mode from the 1st day of the menstrual cycle, 1 tablet per day at the same time without a break for menstruation. Stabilization of the sizes of clinically insignificant myomatous nodes was registered. Intermenstrual spotting lasting from 7 to 12 days, occurring periodically during the menstrual cycle, was observed in the period up to 3 months of using Lactinet in 9 women, in the period up to 6 months – in 3 patients. Amenorrhea was recorded in the period up to 3 months in 15 patients, after 6 months – in 22 patients, after 9 and 12 months – in 25 women. By the 12th month of using Lactinet, premenstrual syndrome and dysmenorrhea were detected in only one woman.
References
1. Prilepskaja V. (ed.) A guide to contraception. Moscow: MEDpress-inform; 2010. 448 p. (in Russian)
2. Tihomirov A. Mioma. Pathogenetic justification of organ-preserving treatment. Moscow: 2013. 320 p. (in Russian)
3. Tihomirov A., Kazenashev V., Ledenkova A. Laktinet is a possible extension of the range of applications. RMJ. Mother and child. 2013;23:1114. (in Russian)
4. Vihljaeva E., Nikolaeva E. The possibility of choosing and acceptability of various methods of contraception after childbirth. Obstetrics and gynecology. 2003;6:20–4. (in Russian)
5. Jaglov V. Contraception after childbirth. Cons. Med. 2001;13(5):86–91. (in Russian)
6. Prilepskaja V. (ed.) A guide to contraception. Moscow: MEDpress-inform; 2006;110–180.
7. Prilepskaja V., Mezhevitinova E., Nazarova N. Hormonal contraception. Moscow: GJeOTAR-Media; 2011;24–46. (in Russian)
8. Savelev E. (2003) Hyperplastic processes of the endometrium in women of reproductive age after cesarean section (PhD Thesis), Kazan. (in Russian)
9. Chivilgina V. (2003) Substantiation of differentiated contraceptive technologies in women in the postpartum period (PhD Thesis), Moscow, 2003.
10. Curtis K.M., Jatlaoui T.C., Tepper N.K. Selected Practice Recommendations for Contraceptive Use, 2016. MMWR Recomm Rep. 2016;65(4):1–66. doi: 10.15585/mmwr.rr6504a1.
11. Tepper N.K., Whiteman M.K., Marchbanks P.A. Progestin-only contraception and thromboembolism: A systematic review. Contraception. 2016;94(6):678–700. doi: 10.1016/j.contraception.2016.04.014.
12. Trussell J. Contraceptive failure in the United States. Contraception. 2011;83(5):397–404. doi: 10.1016/j.contraception.2011.01.021.
13. World Health Organization. Medical Eligibility Criteria for Contraceptive Use. 5th ed. Geneva: World Health Organization; 2015.
14. Kiselev V., Ljashenko A. Molecular mechanisms of regulation of hyperplastic processes. Moscow: Dimitrejd Grafik Grupp; 2005. 348 p. (in Russian)
15. Linde V., Tatarova N. Endometriosis. Patenogenesis, clinical picture, diagnosis and treatment. Moscow: GJeOTAR-Media, 2010. 192 p. (in Russian)
16. Dixon D., Flake G.P., Moore A.B. Cell proliferation and apoptosis in human uterine leiomyomas and myometria. Virchows Arch. 2002;441(1):53–62. doi: 10.1007/s00428-001-0568-7.
17. Dizerega G.S., Barber D.L., Hodgen G.D. Endometriosis: role of ovarian steroids in initiation, maintenance, and suppression. Fertil Steril. 1980;33(6):649–53. doi: 10.1016/s0015-0282(16)44780-1.
18. Practice Committee of American Society for Reproductive Medicine Treatment of pelvic pain associated with endometriosis. Fertil Steril. 2008;90(5 Suppl.):260–269.
